Alzheimer's Disease Clinical Trials in Michigan

22 recruiting studies across 19 cities

All Trials in Michigan

Phase
Trial Phase Location
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's DiseasePhase 3Ann Arbor
Evaluating Novel Healthcare Approaches to Nurturing and Caring for Hospitalized EldersN/AAnn Arbor
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)Phase 3Bloomfield Hills
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)Phase 3Bloomfield Township
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)Phase 3Bloomfield Township
Michigan Healthy Mom (MI-MOM) Pregnancy Improvement Web Application TrialN/ACorunna
Development of a Home Test for Measuring Blood P-tau217 in Alzheimer's Disease Using the Tasso Lancet Device—Dearborn
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR VariantPhase 3Detroit
A Master Protocol Studying Multiple Amyloid-Targeting Therapies in Healthy Participants and Participants With Alzheimer's DiseasePhase 1Farmington Hills
A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)Phase 2Farmington Hills
A Study of LY3439539 in Participants With Alzheimer's DiseasePhase 1Farmington Hills
A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)Phase 1Farmington Hills
A Study of LY4405094 in Healthy Participants and Participants With Alzheimer's DiseasePhase 1Farmington Hills
A Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE)Phase 4Farmington Hills
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)Phase 3Farmington Hills
Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia—Farmington Hills
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease StudiesPhase 3Farmington Hills
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)Phase 3Rochester Hills
ACP-204 in Adults With Alzheimer's Disease PsychosisPhase 2/3Rochester Hills
A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).Phase 3Southfield
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's DiseasePhase 2Sterling Heights
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)Phase 3Troy

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.